Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.68 |
| ▸ | DBF4 | Q9UBU7 | 9/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.45 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31186597 | 1.00 | CDC7 (0.68) | CDC7DBF4HPGDALOX15POLB | |
| SCHEMBL5045055 | 0.85 | CDC7 (0.50) | CDC7DBF4HPGDALOX15 | |
| SCHEMBL21639756 | 0.81 | CDC7 (0.66) | CDC7DBF4HPGDALOX15SLC29A1 | |
| SCHEMBL21639771 | 0.81 | CDC7 (0.66) | CDC7DBF4HPGDALOX15SLC29A1 | |
| SCHEMBL21639769 | 0.81 | CDC7 (0.66) | CDC7DBF4HPGDALOX15SLC29A1 | |
| SCHEMBL31186616 | 0.81 | CDC7 (0.66) | CDC7DBF4HPGDALOX15SLC29A1 | |
| SCHEMBL31186618 | 0.81 | CDC7 (0.66) | CDC7DBF4HPGDALOX15SLC29A1 | |
| SCHEMBL2120063 | 0.81 | CDC7 (0.61) | CDC7DBF4HPGDALOX15POLB | |
| SCHEMBL31186612 | 0.81 | CDC7 (0.61) | CDC7DBF4HPGDALOX15POLB | |
| SCHEMBL9430828 | 0.80 | MAPK14 (0.50) | CDC7DBF4HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604310-B1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-09-11 | — | — | EP | claimed |
| US-20200093828-A1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2020-03-26 | — | — | US | claimed |
| EP-3604310-A1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-02-05 | — | — | EP | claimed |
| EP-3604310-B1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-09-11 | — | — | EP | disclosed |
| US-11446304-B2 | CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2022-09-20 | — | — | US | disclosed |
| US-20200093828-A1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2020-03-26 | — | — | US | disclosed |
| EP-3604310-A1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093828-A1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CDC7, TARDBP, CDC14A | CDC7 1/4885DBF4 171/4885HPGD 4530/4885 |
| US-11446304-B2 | CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions | CDC7, TARDBP, CDC14A | CDC7 1/4885DBF4 171/4885HPGD 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.